GlassScriptPhysician profile
Ashley A Olsen
NPI 1184052813
$9,102.39
in general payments reported to CMS, 2019-2025
57 companies · $1,575 in 2025
The $1,575 reported for 2025 was more than what 90% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $3,608 · 2022: $409 · 2023: $1,670 · 2024: $1,841 · 2025: $1,575.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,951 · Education: $134.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,951.15 |
| Education | $133.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $3,636.74 | 2021-2025 | Enhertu, Injectafer |
| Novartis Pharmaceuticals Corporation | $478.68 | 2023-2025 | |
| Janssen Biotech, INC. | $443.42 | 2023-2025 | Erleada, Akeega, Darzalex |
| Celgene Corporation | $303.47 | 2022-2025 | Reblozyl, Pomalyst |
| Astrazeneca Pharmaceuticals LP | $294.51 | 2022-2025 | Calquence, Tagrisso, Enhertu |
| Eisai INC. | $260.25 | 2022-2025 | |
| E.R. Squibb & Sons, L.L.C. | $235.16 | 2022-2025 | Opdivo, Opdualag, Krazati |
| Regeneron Healthcare Solutions, INC. | $202.39 | 2023-2025 | Libtayo |
| Merck Sharp & Dohme LLC | $198.87 | 2022-2025 | Keytruda, Welireg, Lynparza |
| Exelixis INC. | $166.12 | 2022-2025 | Cabometyx |
| Ucb, INC. | $163.27 | 2021-2024 | Rystiggo |
| Jazz Pharmaceuticals INC. | $157.13 | 2023-2025 | |
| Incyte Corporation | $153.01 | 2022-2025 | Monjuvi, Pemazyre, Zynyz |
| Bayer Healthcare Pharmaceuticals INC. | $131.22 | 2023-2025 | |
| Aveo Pharmaceuticals, INC. | $115.02 | 2024-2025 |
Show all 57 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $110.91 | 2022-2025 | Ultomiris |
| Tersera Therapeutics LLC | $108.70 | 2023-2025 | Zoladex |
| Pfizer INC. | $108.30 | 2023-2025 | |
| Genentech USA, INC. | $104.33 | 2022-2025 | Polivy, Tecentriq, Lunsumio |
| Gilead Sciences, INC. | $98.83 | 2022-2024 | Trodelvy |
| Genmab U.S., INC. | $97.97 | 2024-2025 | Epkinly |
| Seagen INC. | $96.75 | 2023 | Tukysa, Tivdak |
| Abbvie INC. | $96.07 | 2022-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $95.85 | 2023-2025 | Ninlaro, Iclusig |
| Ipsen Biopharmaceuticals, INC | $81.84 | 2024-2025 | Onivyde, Dysport |
| Pharmacyclics LLC, An Abbvie Company | $78.41 | 2022-2023 | Imbruvica |
| Genzyme Corporation | $77.95 | 2022-2024 | |
| Astellas Pharma US INC | $65.93 | 2022-2024 | Xtandi, Xospata |
| Dendreon Pharmaceuticals LLC | $58.12 | 2023-2024 | Provenge |
| Puma Biotechnology, INC. | $57.88 | 2024-2025 | |
| Lilly USA, LLC | $55.70 | 2023 | Verzenio, Retevmo, Jaypirca |
| Taiho Oncology, INC. | $55.29 | 2023-2025 | |
| Rigel Pharmaceuticals, INC. | $54.41 | 2022-2025 | Rezlidhia, Gavreto, Tavalisse |
| Beigene USA, INC. | $53.32 | 2023-2025 | Brukinsa |
| G1 Therapeutics, INC. | $46.08 | 2022-2023 | Cosela |
| Pharmaessentia USA Corporation | $44.98 | 2024 | Besremi |
| Glaxosmithkline, LLC. | $44.12 | 2025 | Ojjaara, Jemperli, Zejula |
| Arcutis Biotherapeutics, INC. | $39.24 | 2024 | Zoryve |
| Sumitomo Pharma America, INC. | $38.11 | 2024 | Orgovyx |
| Karyopharm Therapeutics INC. | $36.95 | 2023-2024 | Xpovio |
| Accord Healthcare, INC. | $31.79 | 2025 | |
| Emd Serono, INC. | $27.52 | 2024 | |
| Deciphera Pharmaceuticals INC. | $27.48 | 2025 | Qinlock |
| Beone Medicines USA, INC. | $27.16 | 2025 | Tevimbra |
| Blueprint Medicines Corporation | $24.06 | 2024 | Ayvakit |
| Adc Therapeutics America, INC. | $21.68 | 2023 | |
| Geron Corporation | $21.35 | 2025 | Rytelo |
| Sobi, INC | $21.14 | 2024 | |
| Mirati Therapeutics, INC. | $21.00 | 2023 | Krazati |
| Pharmacosmos Therapeutics INC. | $20.65 | 2024 | Cosela |
| Progenics Pharmaceuticals, INC. | $18.83 | 2023 | Pylarify |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.63 | 2024 | Gilotrif |
| Servier Pharmaceuticals LLC | $18.15 | 2024 | |
| Cti Biopharma Corp. | $15.46 | 2023 | Vonjo |
| Morphosys, US INC. | $15.07 | 2023 | Monjuvi |
| Azurity Pharmaceuticals, INC. | $13.91 | 2025 | Danziten |
| Array Biopharma INC | $13.21 | 2024 | Mektovi, Lorbrena, Braftovi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashley Olsen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.